Programme

07:15-08:15 Industry Breakfast Symposium – Inqaba Biotec 
Building BRICS: an epidemiologically relevant approach to HPV-based cervical cancer screening – Dr Kreshalen Govender
08:30-09:15 Meet the sponsors / Open Trade (Exhibition Area) Meet the Editors
09:15-09:30 Plenary Session 1 Welcome
09:30-10:00 Pioneering a proactive state of the art response to HIV – Sikhulile Moyo 
10:00-10:30 Host-Directed Therapies to treat TB lung damage – Mohlopheni Jackson Marakalala
10:30-11:00 AMR in 2026 – Marc Mendelson
11:00-11:30 Tea Break
11:30-13:30 Session 1 – Spotlight on Viruses: Past, Present, and Future Threats Session 2 -TB Progress: Smarter Strategies, Sharper Solutions
11:30-11:50 Emerging virusses and virus host interactions – Shashank Tripathi  TB guidelines: An update on paediatric TB – Mo Archary
11:50-12:10 Understanding the origins of COVID 19 and evolution of variants of concern – Marietjie Venter Navigating TB Adverse Drug Reactions – Halima Dawood
12:10-12:30 Characterising HIV infections in declining epidemics – Sikhulelo Moyo TB vaccine update – Thomas Scriba
12:30-12:50 The risks posed by avian influenza viruses – Megan Shaw New TB diagnostics – Grant Theron 
12:50-13:00 124 – Missed in Life, Found in Death:  The Utility of Post-Mortem Minimally Invasive Tissue Sampling (MITS) in Diagnosing Malignancies in Adults with HIV in South Africa – Marguerite Hall 129-Rapid TB and resistance detection in a single test – clinical evaluation of the STANDARD M10 MTB-RIF/INH assay on sputum and tongue swabs – Anura David
13:00-13:10 165 – Serological Responses and Rotavirus Genotype Distribution in Malawian Children presenting with Diarrhoea- End Chinyama 169-Thalidomide as an Adjunctive Therapy for HIV-Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome: A Case Series – Scott Lee-Jones
13:10-13:20 100- Progress and Persistent Gaps in Early Infant HIV Care: A Multi-Year Cascade Analysis –  Valentina Trivella 18 – Pre-existing isoniazid resistance and newly acquired rifampicin-resistant tuberculosis – Ruan Spies
13:20-13:25 162 – Respiratory Virome Profiling in Sudden Unexpected Death in Infancy at Tygerberg Forensic Pathology Mortuary. – Rochelle Croucamp 113 -I491F rpoB gene mutations in isoniazid mono-resistant Mycobacterium tuberculosis – Gabriel Vadivelu
13:25-13:30 207 -A Comparative Metagenomic Investigation of the Viral Diversity in Faecal Samples from Malnourished and Non-Malnourished Children with Gastroenteritis admitted at King Edward VIII Hospital in Durban, KwaZulu-Natal, South Africa – Marcelle Manyi 194 -Predictors of Treatment Success Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline-Based Regimens in a Rural South African Setting – Kgothatso Rakgate
13:30-14:30 Poster Viewing /Lunch (Exhibition Area) Industry  Sponsored Lunch Symposium – Pfizer
Comprehensive coverage of the current epidemiology profile of DTGNB in the SA context. – Dr. Warren Lowman
14:30-16:30 Session 3 – Sexually Transmitted Infections and HIV  Session 4  – Vaccines: From Prevention to Resistance Session 5 – Hard to Crack: Tackling Bone & Joint Infections Session 6 – Barrier to Burden: Strengthening IPC Systems
14:30-14:50 AMR in Neisseria gonorrhoeae and treatment options for resistant gonorrhoea – Ranmini Kularatne The future of childhood vaccines – Rudzani Muloiwa  The importance of a multidisciplinary approach when managing complex bone and joint infections – Kevin Rebe  Panel discussion:  Why IPC systems fail at the bedside?
Magda Mocke, Tebogo Louw, Carika Pretorius and David Weber
14:50-15:10 HIV associated Pneumocystis pneumonia – Ayanda Trevor Mnguni  Health care worker vaccination – Lerato Mpho Sikhosana Surgical approaches for prosthetic joint infection management –  Thomas Hilton  Economics of IPC – Counting the cost of weak systems – Liezl Henning 
15:10-15:30 Mycoplasma Genitalium: An update – Precious Mahlangu  Lifecourse vaccination  – Sipho Dlamini  Candida prosthetic joint infections – Dr Ying Zhao Optimizing laboratory testing in IPC –  David Weber
15:30-15:50 Non-tuberculous mycobacteria in advanced HIV – Halima Dawood  Vaccines for AMR – Denasha Reddy Therapeutic drug monitoring of linezolid – Warren Lowman  The importance of IPC infrastructure and resources – Tracy Douglas
15:50-16:00 116 – Trends in Voluntary Medical Male Circumcision among men seeking Sexually Transmitted Infections service in South Africa, 2020 to 2025 – Nomfundo Banda 117-Epidemiological Investigation of Measles Outbreak, Tshwane District, Gauteng Province, South Africa, June-July 2025. – Francinah Maoko 141- Candida Colonisation in Critically Ill Patients: A Multi-Centre Prospective Cohort Study in Johannesburg, South Africa – Heilisha Dehaloo 9-Genomic characterization of methicillin resistant Staphylococcus aureus (MRSA) clinical isolates from a suspected outbreak in a neonatal unit at an academic hospital in Johannesburg, South Africa – Rispah Chomba
16;00-16:10 187 – Empirical Prescribing for Opportunistic Infections in Hospitalized People with Advanced HIV Disease in South Africa: Findings from the ADVANCE GERMS-SA Cohort – Jean Philippe Suzor 131-Molecular epidemiology and antimicrobial resistance profiles of Enterococcus species isolated from poultry production in South Africa – Ruth Mogokotleng 133-Virulome and plasmid characterisation of hypervirulent Klebsiella pneumoniae isolates from the West –  Amike De Villiers 112-Ribotyping of South African Clostridioides difficile Isolates to Enhance Genomic Epidem – Hlambani Shirinda
16:10-16:20 84 – Role of Epigentic mechanisms in antimicrobial resistance and pathogenicity of clinical urogenital mycoplasmas – Winnie Ramaloko 47-Human Papillomavirus Genotype Landscape Across Cervical Cytology Grades and Impact of HIV Among Women of Eastern Cape Province, South Africa – Sinazo Kondlo 31-Digital disruption of antibiotic stewardship: implementation of a centralised technology-enabled clinical pharmacy model – Angeliki Messina 166-Clinical characteristics and outcomes of invasive antimicrobial-resistant infections in infants <90 days of age – Raheema Adam
16:20-16:25 37-Guidelines uptake, acceptability of a new oral product, and patient pathway in South Africa regarding the sexually transmitted infections Neisseria gonorrhoeae and Chlamydia trachomatis – Camilla Wattrus 160-Emergence of novel G1P[8] rotavirus lineages associated with higher disease severity following vaccine introduction in Malawi – Chimwemwe Mhango 71-Antibiogram and efficacy of antibiotic regimens of bacterial isolates from bone and joint infections in South Africa – Justyna Wojno 24-Genomic insights into antimicrobial resistance in colistin-resistant Gram-negative bloodstream isolates from a tertiary hospital in Soweto – Prenika Jaglal
16:25-16:30 102-A silent burden: MASLD and cardiometabolic risk in adolescents living with HIV – Michael  Christie 170-Descriptive analysis of pertussis surveillance data in Ehlanzeni district, Mpumalanga Province, January 2018 – December 2024 – Lillian Mazibuko 67-Bloodstream infections in adult Intensive Care units across eThekwini KwaZulu-Natal Hospitals – Yesholata Mahabeer 130-Integrating clinical and wastewater surveillance to track Candida auris in South Africa – Silondiwe Nzimande
16:30-17:00 Refreshment Break (Exhibition Area)
17:00-18:00 AGM -IDSSA AGM – SASPID AGM – SASCM AGM – ICSSA AGM – SASV
18:00-19:30 FIDSSA AGM
Evening at leisure
07:00 Registration
07:15-08:15 Industry Sponsored  Breakfast Symposium – Pro Med Diagnostics
Fungal Fun  – Prof Mervyn Mer
08:30-10:30 Plenary Session 2
08:30-09:00 Prioritising fungal infections – Nelesh Govender
09:00-09:30 Paediatric HIV – Mo Archary
09:30-10:00 Leading Beyond the Barrier – Building a Culture of IPC for the Future – David Weber
10:00-10:30 Feedback: WINDSAR  and SAASP /Vindana Chibabhai/ Dena van Den Berg
10:30-11:00 Refreshment Break / Poster viewing
11:00-12:30 Session 7 Young FIDSSA – Next Gen ID:
Mentorship, Momentum, Mastery
Session 8 – Managing infectious in compromised hosts: Burns, neutropenia and beyond Session 9 – Outbreak Alert: Tracking the Re-emerging Pathogens Session 10 – Forgotten No More: Spotlight on Neglected Diseases
11:00-11:20 Career development  – Lerato Mpho Sikhosana, Precious Mahlangu, Gary Reubenson Interdiscliplinary approach to Burns care –  Arifa Parker Tracking N.meningitidis in South Africa – Susan Meiring Hydatid Disease in Southern Africa: When and how to do the PAIR procedure – Jeremy Nel
11:20-11:40 Cultivating a mindset for thriving  in academia, clinical practice and our lives – Dena Van den Bergh ID management of the neutropenic patient –  Lyle Murray Emergance of vaccine preventable diseases – Charlene Lawrence Neglected tropical diseases: Progress, challenges and future directions – Sipho Dlamini
11:40-11:50 179-Two cases of cutaneous toxigenic diphtheria – is there silent spread? – Jamie Colloty Optimising antimicrobial dosing in vulnerable patients – Eric de Cloedt Outbreaks and impact on Health systems – Heather Finlayson Viral Hepatitis  – Tongai Maponga
11:50-12:00 43-Epidemiology and clinical characteristics of non-tuberculous mycobacteria in the Western Cape, South Africa: A retrospective laboratory surveillance study (2016–2022)   – Christoffel Opperman
12:00-12:10 30-Reducing antibiotic duration at scale: outcomes of a multicentre digital intervention in South Africa – Angeliki Messina 164-Phenotypic and Genomic Concordance of Antimicrobial Resistance in Invasive Nontyphoidal Salmonella from South Africa –  Shannon  Williams 20-Whole genome sequencing of Salmonella Typhi isolated from an urban River in Johannesburg, South Africa. – Sanelisiwe Duze 218-Are We Seeing Enough? Laboratory-Based Schistosomiasis Surveillance in South Africa – Bhavani Moodley
12:10-12:20 16-Molecular typing and antimicrobial susceptibility testing of Group B Streptococcus clinical isolates in Pretoria  – Olga  Kgasha 204-Pregnancy-Associated Invasive Group B Streptococcal Disease in South Africa, 2020–2024 – Nombulelo Nkabinde 14-Risk factors for measles re-establishment after achieving elimination – David Durrheim 79-Molecular and genomic characterisation of Campylobacter spp. isolated from pigs on a commercial farm in South Africa in 2019 – Michelle Lowe
12:20-12:25 104-An Unusual Pathogen: Oligella ureolytica Infection in South Africa- A case Report – Lughano Ghambi 150-ECMO-Antimicrobial Dosing Conundrum – Molly Erasmus 103-Genomic insights into non-typhoidal Salmonella from an urban river in Johannesburg, South Africa – Sanelisiwe Duze 88-Improving detection of Balamuthia mandrillaris in South Africa through molecular diagn – Shareen Boughan
12:25-12:30 87 – Integrating Climate Information into Diarrhoeal Disease Preparedness: Opportunities for Climate-Informed Early Warning in South Africa, Botswana and Kenya – Janine Wichmann 190-Tracking Measles and Rubella Risk in South Africa: A Public Dashboard –  Grace Carmichael 32-Onychomycosis in KwaZulu-Natal – is fluconazole still appropriate? –  Yesholata Mahabeer
12:30-13:30 Lunch /  Poster Viewing into lunch (Exhibition Area) Industry Sponsored Lunch Symposium – GSK Industry Sponsored Lunch Symposium – Cepheid
Faster Answers, Better Outcomes: Managing GI Pathogens with Rapid PCR – Dipti Lallubhai – Senior Medical Affairs Manager, Cepheid
13:30-15:00 Plenary Session 3
13:30-14:00 Host-directed antivirals – Megan Shaw
14:00-14:30 Artificial Intelligence in Infectious Diseases: Hype, Hope and Hard Reality – Nicolette du Plessis
14:30-15:00 Topical issues in the STI field – Ranmini Kularatne
15:00-15:30 Refreshment Break / Poster viewing
15:30-17:00 Session 11 – Decoding Disease: Diagnostics that Deliver Session 12 – Global Moves, Local Risks: Travel & Migration Medicine Session 13 – AMR Unmasked: Fighting the Silent Pandemic Session 14  – Paediatric ID Frontiers
15:30-15:50 Diagnostic Stewardship in the Microbiology Laboratory – Ranmini Kularatne When pathogen travel is visa dependent: the spread of meningococcus
Salim Parker
AMR surveillance – what we know and what we don’t know in SA. – Warren Lowman Rethinking Empiric Therapy of Neonatal Sepsis: how to optimise bug-drug match in the era of AMR – Adrie Bekker
15:50-16:10 Helicobacter pylori: current trends and future insights –  Dawood de Costa Emerging travel infections on the horizon  – Lucille Blumberg MDR Klebsiella pneumoniae:novel approaches to tackle a formidable enemy – Denasha Reddy Congenital syphilis update – Lisa Frigati
16:10-16:30 Point of care testing in Microbiology – Andrew Whitelaw Diphtheria and human migration: Lessons to learn –  Arifa Parker AMR in hospital: huge mortality, lots of questions – Jeremy Nel CMV in neonates and young children – Helena Rabie
16:30-16:40 28-Vitek MS performance for Nocardia spp. Identification – Teena Thomas 186-Factors Associated with Knowledge, Attitudes, and Practices among Community Health Workers on Malaria Prevention and Control Measures in Bushbuckridge Sub-district, Mpumalanga Province, 2025 – Sizwe Khumalo 77-Characterization of colistin-resistant Klebsiella pneumoniae isolates from a tertiary-level hospit. – Anjali Silby 8-Paediatric Pneumonia in the Eastern Cape: Epidemiology, Risk Factors and Outcomes from a Five-Year Hospital Study. – Olufunmilayo Olukemi Akapo
16:40-16:50 93-False-positive Mycobacterium tuberculosis complex signals due to Mycobacterium kansasii cross-reactivity on the Roche cobas® MTB assay. – Christoffel Opperman 209 – Meningococcal serogroup C disease outbreak in the West Coast District, Western Cape, South Africa, 2025 – Charlene Lawrence 56-Distribution of van resistance genes among vancomycin-resistant enterococci in Gauteng, South Africa. – Michelle Lowe 157-Viral infections in sudden and unexplained death in infancy cases admitted to the Tygerberg Forensi. – Corena De Beer
16:50-16:55 23-High-resolution profiling reveals extensive co-colonisation and hidden serotype diversity of Klebsiella pneumoniae  –  Lara Van Der Merwe 121-Probable odyssean malaria cluster in a non-endemic district of North West province, South Africa, October 2025 – Patricia Matamba 152-Digitally Enabled, Relationship-Centred Antimicrobial Stewardship: Impact of a Remote Digital Clinical Pharmacy Model in South African Private Healthcare. – Martsu Kriel 33-Neonatal Ventilator-Associated Pneumonia in a Quaternary Centre- a landscape of multi-drug resistance – Yesholata Mahabeer
16:55-17:00 110-Epidemiological trends and patterns of hepatitis A in South Africa, 2019-2024: a national surveillance analysis.- Thobile Khanyile 118-Clinical Epidemiology of Invasive Acinetobacter Infections in Adults. – Sulaiman Hassan 128-Maternal-infant characteristics of preterm and term neonates with bloodstream infections in lower-tier hospitals in South Africa: a cross-sectional study – Vanessa Quan
19:00 Conference Gala Dinner (Ballroom West)
07:15-08:15 Registration / Tea Break
07:15-08:15 Industry Sponsored Breakfast Symposium – Beckman Coulter
The Escalating Battle: AMR and Its Clinical Implications – Dr. Jamal Wadi Al Ramahi
08:30-10:00 Session 15 – Tackling Complexity in Care Session 16 – One Health, One World: Crossing Species, Sharing Solutions
Chair: Wolfgang/Lucille
 
08:30-08:50 SNAP decisions: more than just a different vial – Kessendri Reddy Rabies in Cape fur seals  – Lesley van Helden  
08:50-09:10 Treatment of gram-negative infections in SA in 2026 – Andrew Whitelaw Emerging zoonotic infections – Wolfang Preiser  
09:10-09:30 The in-patient management of the IV drug user – Lyle Murray Climate Change and Infectious Disease – Cheryl Baxter  
09:30-09:50 Management of Candidaemia – Nelesh Govender Living One Health – people, pathogens, pandemics, pasture and prey in practice. – Lucille Blumberg  
09:50-10:00 Q & A Q & A  
10:00-10:15 Refreshment / Comfort Break (Ballroom East Foyer)
10:15-11:00 Plenary  Session 4
10:15-11:00 Rapporteur Session
11:00-12:00 Ethics – Bridging Inequities: Patient-Centered Approaches to Innovative Treatment Access – Marc Blockman
12:00-12:15 Closing remarks
12:15-12:30 Departure and light snacks
13:30   Workshop 2:  WINSA – Womenlift Health Workshop 1: Mycoses interest group

inqaba biotec™, is a unique South African Genomics company that was established in 2002. Our in-house services include oligonucleotides/probes synthesis, Sanger and NGS sequencing, SNP & Methylation analysis, Bioinformatics support, and Phylogenetic & Molecular techniques courses. We are also distributors of strong leading international manufacturers of life-science reagents like New England Biolabs, Eppendorf, Zymo Research and PacBio, as well as molecular diagnostics manufacturers foremost Seegene. These partnerships are built on a shared commitment to scientific excellence, product quality, and reliable technical support across sub-Saharan Africa.

inqaba biotec™, is a unique South African Genomics company that was established in 2002. Our in-house services include oligonucleotides/probes synthesis, Sanger and NGS sequencing, SNP & Methylation analysis, Bioinformatics support, and Phylogenetic & Molecular techniques courses. We are also distributors of strong leading international manufacturers of life-science reagents like New England Biolabs, Eppendorf, Zymo Research and PacBio, as well as molecular diagnostics manufacturers foremost Seegene. These partnerships are built on a shared commitment to scientific excellence, product quality, and reliable technical support across sub-Saharan Africa.

Pfizer Africa: Leading Healthcare Innovation and Addressing Access barriers in Africa

For over 70 years, Pfizer has been present across the African continent, providing innovative medicines and vaccines while forging partnerships with governments and others to ensure robust supply capacity and enable access to help enhance healthcare and improve patient outcomes. By leveraging Pfizer’s extensive experience and resources, we invest in knowledge transfer to upskill healthcare professionals, and help governments drive sustainable improvements in healthcare systems. Dedicated to equity and excellence, our local talent and diverse team strive to advance healthcare infrastructure. Through our enduring commitment and localized approach, we aim to address critical health challenges, improve the quality of life for millions, and build a healthier future for Africans.

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings.

For more information, visit http://www.cepheid.com

Pro Med Diagnostics

Pro Med Diagnostics is a medical diagnostics company specialising in infectious disease with 25 years collective experience

Our focus is the supply of innovative and niche products which offer solutions to the healthcare sector and assist in the improved management of patients.

We are South African registered and based, distributing diagnostic products throughout South Africa, as well as servicing those African countries according to our product suite.

Our offering and expertise:

  • Product training
  • Scientific /technical application and support
  • Events and workshops ensuring customers remain current with all product offerings available
  • Instrumentation technical support
  • On site engineering, software diagnostics and support
  • Specialised freight and logistics (transport specified and specific adherence)
  • SAHPRA and ISO compliant

Beckman Coulter Diagnostics

A global leader in clinical diagnostics, Beckman Coulter Diagnostics has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services.

Beckman Coulter Diagnostics | Beckman Coulter